MIM1

Research use only, not for human use.

A potent, selective small molecule Mcl-1 inhibitor that selectively targets the BH3-binding groove of Mcl-1.

A potent, selective small molecule Mcl-1 inhibitor that selectively targets the BH3-binding groove of Mcl-1; effectively competes with FITC-MCL-1 SAHBA and FITC-BID BH3 for MCL-1ΔNΔC binding with IC50 of 4.7 and 4.8 uM, respectively; shows no activity for Bcl-xL; induces caspase activation and leukemia cell death in the specific context of MCL-1 dependence.

MIM-1 selectively targets the BH3 binding groove of Mcl-1, with Bak-dependent apoptotic activity. To estimate the sensitivity of HA and T98G cells to the apoptosis inhibitor MIM-1, the colorimetric MTT assay is used to detect cell viability and to determine the IC50 value. The IC50 value of the HA cell line is almost 5-fold lower (16.10 μM) compared with the IC50 of the T98G cell line (80.20 μM) after MIM-1 inhibitor treatment.

——

MIM 1 | MIM-1

Angiogenesis

Bcl-2

Bcl-2

Cancer

——

509102-00-5

347.4319

C17H21N3O3S

>98% (HPLC)

10 mM in DMSO

CC1=CSC(=NC2CCCCC2)N1N=CC3=C(C(=C(C=C3)O)O)O

1,2,3-Benzenetriol, 4-[[[2-(cyclohexylimino)-4-methyl-3(2H)-thiazolyl]imino]methyl]-

(-20℃)

With Ice Pack

≥ 2 years